A pretreatment method for streptavidin magnetic beads for electrochemiluminescence detection

By pretreatment of streptavidin magnetic beads, blocking liquid and reagent buffers are used to improve the characteristics of the surface of the magnetic beads, endogenous interference, cross-contamination and sensitivity problems are solved, and the detection of electrochemiluminescence immunoassays is improved. Effect.

CN117949272BActive Publication Date: 2024-11-29NINGBO RUI BIO TECH
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202410137598.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-31
Publication Date
2024-11-29
Estimated Expiration
2044-01-31

AI Technical Summary

Technical Problem

Existing streptavidin magnetic beads have endogenous interference, cross-contamination of measurement pools and limited sensitivity in electrochemiluminescence immunoassays, and commercial magnetic beads have non-specific adsorption and steric position of surfaces without sealing. The resistance affects the detection signal value.

Method used

Using a pretreatment method, the streptavidin magnetic beads, containing buffer, surfactant and macromolecular proteins, are used to clean and dilute streptavidin magnetic beads, including buffer, surfactant and macromolecular proteins, to change the hydrophobicity and charge of the surface of the magnetic beads, and expose the biotin binding site. , and use reagent buffer to prepare solid phase reagents to reduce nonspecific adsorption and cross-contamination.

Benefits of technology

The detection signal value and sensitivity of streptavidin magnetic beads are improved, endogenous interference and cross-contamination of measurement pools are eliminated, and the accuracy and stability of detection are enhanced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117949272B_ABST
    Figure CN117949272B_ABST
Patent Text Reader

Abstract

The invention discloses a pretreatment method for streptavidin magnetic beads, which comprises the following steps: S1: washing the streptavidin magnetic beads with a blocking solution, and then diluting the magnetic beads with the blocking solution and incubating; S2: washing the blocked streptavidin magnetic beads with a reagent buffer, and finally diluting the streptavidin magnetic beads with a reagent buffer to prepare a solid phase reagent. The pretreatment method for commercial streptavidin magnetic beads provided by the invention can change the surface charge and steric hindrance thereof, improve the sensitivity thereof applied to electrochemiluminescence detection reagents, and solve the problems of endogenous interference and cross contamination of the measuring pool.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of chemiluminescent immunoassay, and in particular to a pretreatment method of streptavidin magnetic beads for electrochemiluminescent detection. Background Art

[0002] Electrochemiluminescence immunoassay technology uses magnetic beads as solid phase carriers to connect specific immune complexes. The magnetic beads are adsorbed on the electrode surface through electromagnetic action. Through the action of the electrode, the terpyridine ruthenium labeled on the antibody undergoes redox reaction to generate specific electrochemiluminescence signals, ultimately achieving quantitative detection of specific antigens.

[0003] According to the order of binding between magnetic beads and immune complexes, electrochemiluminescent reagents can be designed into two forms. The first form is to complete the binding of magnetic beads and antibodies first, and the magnetic beads coated with antibodies are used as solid phase reagents to participate in the next step of antigen-antibody reaction. This is also the form commonly used by chemiluminescent reagents. This form of reagent has two major disadvantages: the immune reaction is affected by steric hindrance and the solid phase reagent has poor stability. The other form introduces the biotin-streptavidin system and designs the traditional solid phase reagent into two independent components: streptavidin magnetic beads and biotin-labeled antibodies. The first step of the detection is for the biotin-labeled antibody to complete the immune reaction with the antigen, and the second step is to add streptavidin magnetic beads to capture the immune complex, which can improve both the efficiency of the immune reaction and the stability of the reagent.

[0004] At present, there are many magnetic bead manufacturers on the market that provide commercial streptavidin magnetic beads, but these streptavidin magnetic beads are used as independent reagent components in the electrochemiluminescence detection reagents of the above reaction system. There are still many problems to be solved. First, the surface of the magnetic beads is not sealed, which is easy to produce non-specific adsorption, and the test results are easily affected by endogenous interferences such as hemoglobin, bilirubin, and triglycerides; secondly, the electrochemiluminescence reaction is carried out in the measurement cell, and there are easily magnetic beads on the electrode surface, which leads to an increase in the detection background and even cross-contamination of subsequent sample detection; in addition, the binding of streptavidin magnetic beads and biotin antibodies is also affected by steric hindrance, which affects the reaction signal value and ultimately affects the detection sensitivity.

[0005] Patent CN112986349 discloses a method for modifying and labeling magnetic beads, which modifies the magnetic beads by adding protective groups, and then chemically couples and coats antibodies or streptavidin, thereby controlling the residual charge and hydrophobic groups on the surface of the magnetic beads, and ultimately achieving the effect of reducing the residual magnetic beads on the surface of the electrochemical reaction electrode. The above scheme requires the magnetic beads to be modified first, and then coated with streptavidin, which is ineffective for commercial streptavidin magnetic beads. Patent CN112698025 discloses a method for coating magnetic microparticles with antigens or antibodies, which reduces steric hindrance and improves the chemiluminescent detection signal value by simultaneously using antigens or antibodies labeled with short-arm biotin and long-arm biotin to coat streptavidin magnetic beads.

[0006] So far, there is no economically feasible solution that can simultaneously solve the three problems of endogenous interference, cross-contamination of the measurement cell and limited sensitivity when using streptavidin magnetic beads as electrochemiluminescence immunoassay reagents. Summary of the invention

[0007] The object of the present invention is to provide a blocking agent for electrochemiluminescence immunoassay and its use, so as to solve the problems of endogenous interference, cross contamination of measuring pool and limited sensitivity when streptavidin magnetic beads are used in electrochemiluminescence immunoassay reagents.

[0008] The purpose of the present invention is achieved through the following technical solutions:

[0009] A pretreatment method for streptavidin magnetic beads, the pretreatment method comprising the following steps:

[0010] S1: Wash the streptavidin magnetic beads with blocking solution, then dilute the magnetic beads with blocking solution and incubate;

[0011] S2: The blocked streptavidin magnetic beads are washed with reagent buffer, and finally the streptavidin magnetic beads are diluted with reagent buffer to prepare a solid phase reagent.

[0012] Furthermore, the blocking solution components include a buffer, a surfactant, a macromolecular protein mixture and a small molecule amino acid.

[0013] Furthermore, the blocking solution comprises 50 mM Tris, 0.5% sodium caseinate, 0.1% glycine, and 0.02% sodium dodecylaminopropionate, and the pH of the blocking solution is 8.0.

[0014] Furthermore, the incubation conditions are: incubation at 37° C. for 3 hours.

[0015] Furthermore, the reagent buffer comprises a buffer, a protein, a surfactant and a preservative.

[0016] Furthermore, the reagent buffer also includes a saline solution.

[0017] Furthermore, the salt solution is sodium chloride or magnesium chloride.

[0018] Furthermore, the buffer in the reagent buffer is 10-50 mM phosphate buffer, the protein is BSA, the surfactant is Tween 20, the preservative is PC300, and the pH of the reagent buffer is 6.5-7.5.

[0019] Furthermore, in step S1, the streptavidin magnetic beads are washed three times with a blocking solution; in step S2, the blocked streptavidin magnetic beads are washed three times with a reagent buffer, and the solid phase reagent is a liquid mixture containing streptavidin magnetic beads.

[0020] Application of any of the above streptavidin magnetic bead pretreatment methods in electrochemiluminescence detection.

[0021] Commercial streptavidin magnetic beads are usually not blocked, or there is no targeted screening of magnetic bead pretreatment methods for application in electrochemiluminescence reagents, resulting in abnormal morphology of streptavidin coated on the surface of the magnetic beads, so that part of the binding site of streptavidin and biotin is blocked, resulting in the binding process of streptavidin magnetic beads and biotin antibodies being affected by steric hindrance, reducing the sensitivity of the reagent. In addition, streptavidin magnetic beads are generally obtained by chemical coupling of carboxyl magnetic beads or tosyl magnetic beads and streptavidin. The carboxyl or tosyl group is connected to the polystyrene on the surface of the magnetic beads through an alkane chain. The surface of the magnetic beads without blocking usually shows hydrophobicity, which makes the surface of the magnetic beads prone to nonspecific adsorption. The test results are easily affected by endogenous interferences such as hemoglobin. At the same time, nonspecific adsorption may also occur between the magnetic beads and the electrodes, resulting in the magnetic beads remaining on the electrode surface and causing cross-contamination of the measuring pool.

[0022] The present invention maintains the correct form of streptavidin on the surface of magnetic beads and fully exposes the site of biotin binding by adding macromolecular proteins and small molecule amino acids in the confining solution at the same time. In addition, a surfactant is also added to the confining solution to change the hydrophobicity of the surface of the magnetic beads. At the same time, the surfactant can also play the role of a detergent, remove non-specific adsorption, reduce the influence of endogenous interferences on the test results, and reduce the residual magnetic beads on the electrode surface. In order to better support the streptavidin on the surface of the magnetic beads and fully expose its biotin binding site, the present invention selects a protein mixture composed of multiple molecular weights, i.e. sodium caseinate. Sodium caseinate contains a variety of macromolecular proteins with a relative molecular weight of 75 to 375 kDa, and proteins of different molecular weights can effectively fill the gaps on the surface of streptavidin magnetic beads. At the same time, sodium caseinate also has similar properties to surfactants, which can reduce the non-specific adsorption on the surface of magnetic beads to a certain extent.

[0023] The beneficial effects of the present invention are:

[0024] 1. The present invention provides a pretreatment method for streptavidin magnetic beads, which improves a variety of commercial streptavidin magnetic beads. By blocking the commercial streptavidin magnetic beads, the surface steric hindrance is changed, so that the surface streptavidin maintains the correct shape, fully exposes the biotin binding site, improves the detection signal value, and also improves the sensitivity of the electrochemiluminescence detection reagent.

[0025] 2. The present invention provides a method for pretreating streptavidin magnetic beads, which performs a sealing treatment on commercial streptavidin magnetic beads to change the surface charge and hydrophobicity of the magnetic beads, remove non-specific adsorption, and eliminate endogenous interference and cross-contamination of the measurement pool.

[0026] 3. The pretreatment method of streptavidin magnetic beads provided by the present invention is simple to operate and is very suitable for promotion and application in electrochemiluminescence detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is a comparison chart of the test results of the FPSA solid phase reagent prepared in Comparative Example 7 of the present invention and the comparison reagent FPSA;

[0028] Figure 2 This is a comparison chart of the detection results of the FPSA solid phase reagent prepared in Example 4 of the present invention and the comparison reagent FPSA. DETAILED DESCRIPTION

[0029] Definitions of terms used in the present invention: Unless otherwise stated, the initial definitions provided for the terms in this document apply to the terms throughout the specification; for terms that are not specifically defined in this document, the meaning that a person skilled in the art would give them should be given based on the disclosure and context.

[0030] The reagents and equipment used in the present invention are all known products or obtained by purchasing commercially available products.

[0031] The nouns in the following embodiments are explained as follows:

[0032] NSE: neuron-specific enolase; AFP: alpha-fetoprotein; PSA: prostate-specific antigen; FPSA: free prostate-specific antigen; RLU: relative luminescence unit.

[0033] Solid phase reagent: A liquid mixture containing streptavidin magnetic beads that captures the immune complex formed after the antigen-antibody reaction by binding to the biotin-labeled antibody in the electrochemiluminescence detection technology.

[0034] Streptavidin Magnetic Beads A Manufacturer: JSR

[0035] Streptavidin Magnetic Beads B Manufacturer: Agilent Technologies

[0036] Streptavidin Magnetic Beads C Manufacturer: Hangzhou Boyue Biotechnology Co., Ltd.

[0037] The basic principle of electrochemiluminescence detection reaction:

[0038] The sample and the biotin labeling reagent and the ruthenium labeling reagent form an antigen-antibody immune complex; the addition of the solid phase reagent allows the antigen-antibody immune complex to be adsorbed to the surface of the magnetic beads through the combination of biotin and streptavidin to form a reactant; the reactant is transferred to a measuring cell, an electromagnetic field is applied to the measuring cell, the magnetic beads are adsorbed on the surface of the electrode through the electromagnetic field, and the terpyridine ruthenium not bound to the magnetic beads is removed by the cleaning solution flowing in the measuring cell; an electric field is applied to the measuring cell, and the terpyridine ruthenium realizes an electrochemiluminescence reaction through the combined action of the electrode and tripropylamine, the generated photons are captured by the instrument and converted into relative luminescence units RLU, and finally the conversion between the concentration of the antigen or antibody to be tested in the sample and the electrochemiluminescence signal is realized, and the concentration of the sample to be tested is determined.

[0039] In order to more clearly illustrate the technical solution of the present invention, the specific implementation methods are described as follows:

[0040] Embodiment 1

[0041] S1: Take a certain amount of streptavidin magnetic beads A, wash them three times with blocking solution 1, dilute the magnetic beads to 10 mg / mL with blocking solution 1, and incubate at 37°C for 3 hours to block the magnetic beads;

[0042] S2: Wash the blocked magnetic beads three times with reagent buffer, and finally dilute the magnetic beads to 0.6 mg / mL with NSE reagent buffer to prepare NSE solid phase reagent.

[0043] Blocking solution 1: 50 mM Tris, pH 8.0, 0.5% sodium caseinate, 0.1% glycine, 0.02% sodium dodecylaminopropionate.

[0044] NSE reagent buffer: 50 mM phosphate buffer, pH 6.5, 0.5% BSA, 5 mM magnesium chloride, 0.05% Tween 20, 0.1% PC300.

[0045] Comparative Example 1:

[0046] Comparative Example 1 is based on Example 1, except that: the streptavidin magnetic beads A are directly prepared into a solid phase reagent without blocking treatment.

[0047] Comparative Example 2:

[0048] Comparative Example 1 is based on Example 1, except that: Streptavidin magnetic beads A are blocked with blocking solution 2.

[0049] Blocking solution 2: 50 mM Tris, pH 8.0, 2% BSA, 0.1% glycine, 0.05% Triton X-100.

[0050] The solid phase reagents prepared in Example 1, Comparative Example 1 and Comparative Example 2 were respectively combined with NSE biotin labeling reagent and NSE ruthenium labeling reagent to form detection reagents, and the RLU values ​​were tested on an electrochemiluminescence immunoassay. The differences in RLU values ​​are shown in Table 1.

[0051] At the same time, the three groups of reagents were tested for the cross contamination rate of the measuring pool using the test method of carryover contamination. Three high-value samples were tested in parallel, and then three blank samples were tested in parallel. The cross contamination rate was calculated (cross contamination rate = (RLU3-RLU6) / (RLU4-RLU6)*100%). The results are shown in Table 2. Since the electrochemiluminescence immunoassay analyzer used in this experiment uses disposable pipette tips to absorb samples and reagents, there is no carryover contamination of the sample aspiration needle, so the abnormal measurement results are caused by cross contamination in the measuring pool.

[0052] Table 1

[0053]

[0054] The data in Table 1 show that, compared with Comparative Examples 1 and 2, in Example 1, the streptavidin magnetic beads A were blocked with blocking solution 1, and the RLU values ​​of the NSE reagent detection calibrants S1 to S7 were increased by an average of 50% and 35%, while the background RLU value was kept unchanged.

[0055] Table 2

[0056]

[0057] According to the data in Table 1 and Table 2, the RLU value of the blank calibrator S0 is about 600. After the high-value calibrator S7 is measured in Comparative Example 1, the blank calibrator S0 is measured, and the RLU reaches about 20000, which obviously indicates cross contamination. The data in Table 2 show that compared with Comparative Example 1, the cross contamination rate of Comparative Example 2 is significantly reduced, but cross contamination still exists, while Example 1 can completely eliminate the cross contamination of the measuring pool.

[0058] The results of Example 1 and Comparative Examples 1 and 2 show that the use of a blocking solution mixed with macromolecular proteins, small molecule amino acids and surfactants to block streptavidin magnetic beads A can improve the sensitivity of NSE reagents in measuring samples to a certain extent, while reducing the cross contamination of the measuring pool caused by residual magnetic beads on the electrode surface. Compared with the combination of BSA and non-ionic surfactant Triton X-100, sodium caseinate and amino acid surfactant sodium dodecylaminopropionate have a more obvious effect on improving detection sensitivity and reducing cross contamination of the measuring pool.

[0059] Embodiment 2:

[0060] S1: Take a certain amount of streptavidin magnetic beads B, wash them three times with blocking solution 1, dilute the magnetic beads to 10 mg / mL with blocking solution 1, and incubate at 37°C for 3 hours to block the magnetic beads;

[0061] S2: Wash the blocked magnetic beads three times with reagent buffer, and finally dilute the magnetic beads to 0.8 mg / mL with AFP reagent buffer to prepare AFP solid phase reagent.

[0062] AFP reagent buffer: 10 mM phosphate buffer, pH 7.2, 0.5% BSA, 0.9% sodium chloride, 0.05% Tween 20, 0.1% PC300.

[0063] Comparative Example 3:

[0064] Comparative Example 3 is based on Example 2, except that: the streptavidin magnetic beads B are directly prepared into a solid phase reagent without blocking treatment.

[0065] Comparative Example 4:

[0066] Comparative Example 4 is based on Example 2, except that: the streptavidin magnetic beads B are blocked with blocking solution 3.

[0067] Blocking solution 3: 50 mM Tris, pH 8.0, 0.5% γ-globulin, 0.1% glycine, 0.05% Tween 20.

[0068] The solid phase reagents prepared in Example 2, Comparative Example 3 and Comparative Example 4 were respectively combined with AFP biotin labeling reagent and AFP ruthenium labeling reagent to form detection reagents, and the RLU values ​​were tested on an electrochemiluminescence immunoassay. The differences in RLU values ​​are shown in Table 3.

[0069] At the same time, the three groups of reagents were tested for hemoglobin interference. The test method is as follows: 5000 mg / dL hemoglobin solution was prepared with normal saline, and then 5 serum samples were taken, each serum sample was divided into two parts, one of which was added with the above hemoglobin solution at a volume ratio of 1:9 (the final hemoglobin concentration added to the serum sample was 500 mg / dL), and the other was added with normal saline at the same ratio as the control group. The relative deviation of the two groups of test results is the interference rate of hemoglobin on the AFP test. The results are shown in Table 4.

[0070] Table 3

[0071]

[0072] The data in Table 3 show that, compared with Comparative Examples 3 and 4, when the streptavidin magnetic beads B in Example 2 were blocked with blocking solution 1, the RLU value of the sample detected by the AFP reagent increased by an average of 80% and 65%, and the background RLU value increased by less than 10%.

[0073] Table 4

[0074]

[0075] The data in Table 4 show that the AFP sample detected in Comparative Example 3 was obviously interfered by hemoglobin, with an interference rate as high as 15%, while the interference rate in Comparative Example 4 was slightly reduced. However, the interference of hemoglobin was eliminated by using the improved reagent in Example 2.

[0076] The results of Example 2 and Comparative Examples 3 and 4 show that the use of a blocking solution mixed with a macromolecular protein, a small molecule amino acid and a surfactant to block the streptavidin magnetic beads B can improve the sensitivity of the AFP reagent to test the sample to a certain extent, while reducing the interference of hemoglobin on the test results. Compared with the combination of γ-globulin and Tween 20, sodium caseinate and sodium dodecylaminopropionate have a more obvious effect on improving the detection sensitivity and eliminating the interference of hemoglobin.

[0077] Embodiment 3:

[0078] S1: Take a certain amount of streptavidin magnetic beads C, wash them three times with blocking solution 1, dilute the magnetic beads to 10 mg / mL with blocking solution 1, and incubate at 37°C for 3 hours to block the magnetic beads;

[0079] S2: Wash the blocked magnetic beads three times with reagent buffer, and finally dilute the magnetic beads to 0.7 mg / mL with PSA reagent buffer to prepare PSA solid phase reagent.

[0080] PSA reagent buffer: 10 mM phosphate buffer, pH 7.4, 0.5% BSA, 0.05% Tween 20, 0.1% PC300.

[0081] Comparative Example 5:

[0082] Comparative Example 5 is based on Example 3, except that: the streptavidin magnetic beads C are directly prepared into a solid phase reagent without blocking treatment.

[0083] Comparative Example 6:

[0084] Comparative Example 6 is based on Example 3, except that: the streptavidin magnetic beads C are blocked with blocking solution 4.

[0085] Blocking solution 4: 50 mM Tris, pH 8.0, 2% glycine, 0.05% Brij35.

[0086] The test solid phase reagents prepared in Example 3, Comparative Example 5 and Comparative Example 6 were respectively combined with PSA biotin labeling reagent and PSA ruthenium labeling reagent to form detection reagents, and the RLU values ​​were tested on an electrochemiluminescence immunoassay instrument. The differences in RLU values ​​are shown in Table 5.

[0087] At the same time, the three groups of reagents were tested for triglyceride interference. The test method is as follows: fat emulsion is used to simulate triglyceride interference, and the fat emulsion is diluted to 30000 mg / dL with normal saline, and then 5 serum samples are taken, each serum sample is divided into two parts, one of which is added with the above concentration of fat emulsion at a volume ratio of 1:19 (the final fat emulsion concentration added to the serum sample is 1500 mg / dL), and the other is added with the same proportion of victory saline as a control group. The relative deviation of the two groups of test results is the interference rate of triglycerides on PSA test, and the results are shown in Table 6.

[0088] Table 5

[0089]

[0090] The data in Table 5 show that, compared with Comparative Examples 5 and 6, when the streptavidin magnetic beads C in Example 3 were blocked with blocking solution 1, the RLU value of the sample detected by the PSA reagent increased by an average of 78% and 75%, and the background RLU value remained basically unchanged.

[0091] Table 6

[0092]

[0093] The data in Table 6 show that the PSA sample detection in Comparative Example 5 is obviously interfered by triglycerides, with an interference rate of about 25%. In Comparative Example 6, the interference of triglycerides on PSA detection is improved to a certain extent, and the interference of triglycerides is eliminated by using the improved reagent in Example 3.

[0094] The results of Example 3 and Comparative Examples 5 and 6 show that after blocking, the streptavidin magnetic beads C reduce the interference of triglycerides on the detection results to a certain extent, but it can also be found that the detection sensitivity of the PSA reagent is not improved by using a blocking solution that does not contain large molecular proteins. Compared with the blocking solution that does not contain large molecular proteins, the combination of sodium caseinate, small molecule amino acids and sodium dodecylaminopropionate has a significant effect on improving the sensitivity, and the combination is also more effective in eliminating the interference of triglycerides.

[0095] Embodiment 4:

[0096] S1: Take a certain amount of streptavidin magnetic beads C, wash them three times with blocking solution 1, dilute the magnetic beads to 10 mg / mL with blocking solution 1, and incubate at 37°C for 3 hours to block the magnetic beads;

[0097] S2: Wash the blocked magnetic beads three times with reagent buffer, and finally dilute the magnetic beads to 0.7 mg / mL with FPSA reagent buffer to prepare FPSA solid phase reagent.

[0098] FPSA reagent buffer: 10 mM phosphate buffer, pH 7.4, 0.5% BSA, 0.05% Tween 20, 0.1% PC300.

[0099] Comparative Example 7:

[0100] Comparative Example 7 is based on Example 4, except that: the streptavidin magnetic beads C are directly prepared into a solid phase reagent without blocking treatment.

[0101] The solid phase reagents prepared in Example 4 and Comparative Example 7 were respectively combined with FPSA biotin labeling reagent and FPSA ruthenium labeling reagent to form detection reagents, and the RLU values ​​were tested on an electrochemiluminescence immunoassay instrument. The differences in RLU values ​​are shown in Table 7.

[0102] At the same time, 8 hemolytic samples, 8 lipid turbidity samples and 9 high bilirubin samples, a total of 25 interference samples, were taken, and the concentration was tested using the FPSA reagent of Example 4, the FPSA reagent of Comparative Example 7 and the purchased Roche comparison reagent. Detection process: The FPSA reagent of Example 4, the FPSA reagent of Comparative Example 7 and the comparison reagent were calibrated with their respective matching calibration products, and then the 25 interference samples were tested in turn. The instrument automatically calculated the sample concentration value based on the RLU value of the sample test and the calibration curve. The sample test results of Example 4 and the comparison reagent were compared and analyzed, and the sample test results of Comparative Example 7 and the comparison reagent were also compared and analyzed. The comparison results of the two groups of reagents are shown in Figure 2. Figure 1 and Figure 2 .

[0103] Table 7

[0104]

[0105] The data in Table 7 show that, compared with Comparative Example 7, when the streptavidin magnetic beads C in Example 4 were blocked with blocking solution 1, the RLU value of the sample detected by the FPSA reagent increased by an average of 95%, and the background RLU value remained basically unchanged.

[0106] Figure 1 and Figure 2The data show that for hemolytic samples, lipophilic samples and high bilirubin samples with endogenous interfering substances in clinical practice, the comparison correlation coefficient R2 between Comparative Example 7 and the comparison reagent is 0.9407, and the correlation is poor, indicating that endogenous interfering substances have a relatively large impact on the test results of clinical samples. However, using the improved reagent of Example 4, the test results of samples with endogenous interfering substances are highly consistent with those of the comparison reagent, and the correlation coefficient R2 is close to 0.99.

[0107] The results of Examples 1 to 4 are significantly different from those of Comparative Examples 1, 3, 5, and 7, indicating that the pretreatment method of the present invention is applied to three different commercial streptavidin magnetic beads, and is applied to four projects of NSE, AFP, PSA, and FPSA, which can significantly improve the detection sensitivity of the reagent. At the same time, it can solve the endogenous interference problem of ordinary streptavidin magnetic beads directly applied to electrochemiluminescence detection reagents and the cross-contamination problem of the measuring pool, thereby improving the accuracy of sample detection.

[0108] There are differences in the results of Examples 1 to 3 and Comparative Examples 2, 4 and 6, indicating that compared with not adding macromolecular proteins or adding only macromolecular proteins of a single molecular weight to the blocking solution, the combination of a protein mixture containing a plurality of molecular weight combinations and a combination of small molecule amino acids and surfactants selected in the present invention has a more obvious effect on improving detection sensitivity, improving cross contamination of the measuring pool and improving endogenous interference.

Claims

1. A method for pretreating streptavidin magnetic beads, characterized in that: The pretreatment method comprises the following steps: S1: Wash the streptavidin magnetic beads with blocking solution, then dilute the magnetic beads with blocking solution and incubate; S2: The blocked streptavidin magnetic beads are washed with a reagent buffer, and finally the streptavidin magnetic beads are diluted with a reagent buffer to prepare a solid phase reagent; The blocking solution components include buffer, surfactant, macromolecular protein mixture and small molecule amino acid; the incubation conditions are: incubation at 37°C for 3 hours; The blocking solution comprises 50 mM Tris, 0.5% sodium caseinate, 0.1% glycine and 0.02% sodium dodecylaminopropionate, and the pH of the blocking solution is 8.0; the reagent buffer comprises a buffer, a protein, a surfactant and a preservative; The streptavidin magnetic bead pretreatment method is applied in electrochemiluminescence detection.

2. The pretreatment method of streptavidin magnetic beads according to claim 1, characterized in that: The reagent buffer also includes a saline solution.

3. The pretreatment method of streptavidin magnetic beads according to claim 2, characterized in that, The salt solution is sodium chloride or magnesium chloride.

4. The pretreatment method of streptavidin magnetic beads according to claim 1, characterized in that: The buffer in the reagent buffer is 10-50 mM phosphate buffer, the protein is BSA, the surfactant is Tween 20, the preservative is PC300, and the pH of the reagent buffer is 6.5-7.

5.

5. The pretreatment method of streptavidin magnetic beads according to claim 1, characterized in that: In step S1, the streptavidin magnetic beads were washed three times with blocking solution; In step S2, the blocked streptavidin magnetic beads are washed three times with a reagent buffer, and the solid phase reagent is a liquid mixture containing streptavidin magnetic beads.

Citation Information

Patent Citations

  • Chemiluminescent quantitative detection kit for detecting insulin in serum / plasma and preparation method and detecting method of chemiluminescent quantitative detection kit

    CN108896772A

  • Acridinium ester chemiluminescence-based streptavidin magnetic bead-biotin amplification reaction system and detection kit

    CN110146692A

  • Confining liquid for liquid chip, confining method and application

    CN110836965A

  • Sealing agent and sealing method

    CN111044716A

  • Coupling method of immune magnetic particles, diluent and application

    CN113311154A